Arkansas Plans Lawsuit Over Antipsychotics

brain.jpgDustin McDaniel told lawmakers two days ago that he’s planning to file a lawsuit within a month seeking up to $600 million against Eli Lilly, AstraZeneca, and Johnson & Johnson’s Jannsen Pharmaceutica over “improper and unlawful marketing” of antipsychotics paid for by the state Medicaid program, The Arkansas Democrat & Gazette reports. Some people shouldn’t have been given the meds and have developed side effects, he reportedly said.

McDaniel also told the state’s Legislative Council he’s taking the unusual step of contracting with a private law firm, Bailey Perrin Bailey of Houston, to take the lead in the litigation, but the firm will bear all the expenses while receiving 15 percent of any award as a fee. “It’s extraordinarily reasonable for the quality of work we’re going to get,” McDaniel said. “This particular matter is so large that frankly the AG’s office could not handle it internally. If (the suit) is not successful we don’t owe a dollar.” He added that the firm is handling similar litigation for six other states.

A national coalition of about 30 state attorneys general is involved in a similar investigation of antipsychotic drug marketing but McDaniel told the paper he declined to join that effort because he feared Arkansas would “be lost in the shuffle.”

A letter McDaniel wrote to the council says “substantial evidence” exists to support a claim that the drugmakers improperly marketed their drugs - Zyprexa, Risperdal and Seroquel. The companies didn’t respond to messages left by the paper. McDaniel told reporters after the meeting that researchers have known since the 1950 s that anti-psychotic drugs had serious side effects, including weight gain, hypoglycemia and Type II diabetes. “What (the drugmakers) did was intentionally hide that and downplayed the efficacy of alternatives,” he said.

McDaniel said the companies engaged in a “marketing scheme that was very effective to where a drug that was never approved by the (the FDA) for children…the elderly…or run of the mill behavioral disorders like depression, all of a sudden was touted to America’s doctors, Arkansas ’ doctors, as a miracle drug. So, a child that has (attention deficit disorder) is taking a drug that was never authorized for that child, causing serious complications… that could last a lifetime.”

He said the state Medicaid program has spent $ 200 million on those drugs over the last eight years and, under Arkansas’ Medicaid fraud law, the state could collect three times that much. But it’s unclear at this point what percentage of those Medicaid prescriptions were necessary and what percentage were improper, said McDaniel’s chief deputy, Justin Allen. A McDaniel spokesman couldn’t say late Friday what the statute of limitations is on Medicaid fraud cases.

McDaniel said what generally happens is that pharmaceutical representatives will push doctors to prescribe the drugs based on what the company tells them. “Technically, does the doctor have liability if he thereafter prescribes it ? Maybe, but the concern for the state is the overall marketing scheme, and those who made profit over it,” he said. “The (state) Medical Board should certainly give consideration regarding how much trust is placed in pharmaceutical reps.” McDaniel added that the prescriptions in questions were “off-label.”

Scott Smith, a lobbyist for the Arkansas Medical Society, a doctors’ trade association, said that means for uses not approved by the FDA. “It’s my understanding that physicians can prescribe medicines for uses not approved by the FDA for a particular ailment but the distinction is that pharmaceutical companies are not supposed to be marketing physicians for that,” Smith said.

Waiting for FDA approval before prescribing the drugs can take years and waiting could mean “life or death” for some patients, he said. Smith said he hasn’t heard of any problems with Zyprexa, Risperdal and Seroquel in Arkansas. Officials at the Arkansas State Medicaid Board couldn’t be reached for comment late Friday. Arkansas Medicaid Director Roy Jeffus and a Department of Human Services spokesman didn’t return messages Friday.

According to a St. Petersburg Times report in July, the Medicaid program in Florida last year spent $ 27. 5 million on anti-psychotic drugs for children, an increase of nearly 500 percent over the last seven years. The paper wrote that Medicaid and insurance programs have pushed the drugs as a less costly alternative to psychotherapy for children, but some psychiatrists say the drugs are too risky for children because the young patients’ brains are still developing.

During the legislative meeting, Sen. Ruth Whitaker, R-Cedarville, asked McDaniel about the law firm’s qualifications. McDaniel said he started working on the issue in the days before he was sworn in in January. He said only about eight firms nationwide are qualified to handle such litigation. He said he interviewed applicants for the contract “exhaustively” and the Houston firm rose to the top because it is already working on the issue in representing Pennsylvania, South Carolina, Alaska, New Mexico, Louisiana and Mississippi.

The other firms that applied for the contract were: The Miller Firm of Orange, Va.; Allen L. Rothenbert of Yardley, Pa.; Schiffrin Barroway Topaz & Kessler of Radnor, Pa.,and Heninger Garrison Davis of Birmingham, Ala.

“This is going to be massive litigation and it was not selected willy-nilly,” he told Whitaker. And McDaniel emphasized that his office, not the Houston firm, would have final say on major decisions involving the lawsuit.

Problems arose in 1998 when former Attorney General Winston Bryant arranged for a San Diego firm to help him in the state’s litigation against tobacco companies. But Bryant never used the firm and settled the litigation along with other states. Arkansas’ expected take was between $ 50 million and $ 60 million a year. The firm sued the state, saying it had done work for Arkansas and deserved to be compensated, but the state prevailed in court.

Since then, the attorney general’s office has only used one private firm on a contingency basis and that was under Attorney General Mark Pryor and involved asbestos claims. That was Dies & Hile LLP of Orange, Texas, said spokesman Gabe Holmstrom. McDaniel said he expects no problems with the Houston firm.

“This law firm has never contributed to my campaigns…nor the lawyers in the firm, nor their spouses, nor their kids, I think,” he told reporters. “If there is a kid or a cousin that slipped through we didn’t know about it.”

Tags:, , , , , , , , ,

You can follow any responses to this entry through the RSS feed.
You can leave a response, or trackback from your own site.

3 Responses

  1. Lisa

    Where is the New Jersey Attorney General on this issue?!
    New Jersey Residents,Infants, Toddlers, Teens and Adults are being Prescribed these drugs at alarming rates,WHY?!

    New Jersey shouldnt be a bottomless money pit for these drug companies!!!!!!

  2. Amy

    What about Florida? 2005 was the last I heard of this:

    In June 2005, Lilly received a subpoena from the office of the Attorney General, Medicaid Fraud Control Unit, of the State of Florida, seeking production of documents relating to sales of Zyprexa and their marketing and promotional practices with respect to Zyprexa.

  3. FraudPI

    Since Big Pharma has such a large presence in NJ, and pays correspondingly large sums in taxes and political contributions, I doubt NJ politicians consider it judicious to hold Pharma Manufacurer’s accountable for their actions.

    After all, NJ legislators haven’t even passed a State False Claims Act, which would encourage employees to report fraud, and would enable NJ to collect tens, or even hundreds of millions of dollars in Medicaid overpayments.

    Whether or not NJ takes an active role in this litigation, they’ll most likely still collect their portion of any settlement.

Leave a Reply


Pharmalot archives